-
If a judge orders Google to sell Chrome, it could dramatically upend the multibillion-dollar online search business.
-
One of the world's richest people has been indicted on charges he duped investors in a massive solar energy project in India by concealing that it was being facilitated by an alleged bribery scheme.
-
The U.S. House Committee on Ethics is deadlocked on whether to release its report into former Rep. Matt Gaetz, whose nomination to serve as Trump's attorney general has been plagued by controversy.
-
The case over the killing of a Georgia nursing student fueled the national debate over immigration during this year's presidential race.
-
President-elect Donald Trump tapped Matthew Whitaker as his ambassador to the North Atlantic Treaty Organization, which Trump has long criticized for taking advantage of U.S. defense spending.
-
Field goals of 50 yards or longer used to be a rare thing in the NFL. But this season, kickers are hitting them at a record 72% clip — and head coaches are trying them far more often than ever before.
-
Officials say Monsignor Jamie Gigantiello was disciplined for mishandling $1.9 million in parish funds. He faced scrutiny last year for letting Carpenter film a music video at his Brooklyn church.
-
Former Secretary of Defense Chuck Hagel says "a lack of any government experience is an issue" when leading the largest institution in the world.
-
Case counts for Oropouche virus are still low but rising dramatically. What's going on? And then there's a study that raises the possibility that insect bites aren't the only way the virus can spread.
-
What we know about Linda McMahon, President-elect Donald Trump's pick to lead the U.S. Department of Education. And, science-backed tips to bridge political divides.
-
A 2022 survey found growing numbers of Republicans and Democrats think the other side is immoral and dishonest. Psychology and neuroscience research offers tools to help bridge that divide.
-
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.